Literature DB >> 10632047

The anticonvulsant activities of N-benzyl 3-methoxypropionamides.

S V Andurkar1, J P Stables, H Kohn.   

Abstract

We recently reported that the ED50 value for (R,S)-2,3-dimethoxypropionamide (1) in the maximal electroshock (MES)-induced seizure test in mice was 30 mg/kg (Choi, D.; Stables, J.P., Kohn, H. Bioorg. Med. Chem. 1996, 4, 2105). This value is comparable to that observed for phenobarbital (ED50 = 22 mg/kg). Compound 1 is structurally similar to a class of MES-selective anticonvulsant agents, termed functionalized amino acids (2), that were developed in our laboratory. The distinguishing feature of 2 is the differential activities observed for enantiomers. In this study, we asked whether comparable differences in activities were observed in the MES-induced seizure test for (R)- and (S)-1. We developed stereospecific syntheses for these enantiomers and showed that both compounds exhibit nearly equal anticonvulsant activity in mice (i.p.) (MES ED50 = 79-111 mg/kg). The surprisingly high ED50 values for (R)- and (S)-1 required our redetermining the ED50 value for (R,S)-1. We revised this value to 79 mg/kg. A limited structure-activity relationship study for 1 was conducted. Special attention was given to the C(2) methoxy unit in 1. We found that replacement of this moiety led to only modest differences in the MES activities upon ip administration to mice. Significantly, we observed an enhancement in the anticonvulsant activity for (R,S)-N-benzyl 2-hydroxy-3-methoxypropionamide ((R,S)-6) upon oral administration to rats ((R,S)-6: mice (i.p.) ED50 > 100, < 300 mg/kg; rat (oral) ED50 = 62 mg/kg). The activities of 3-methoxypropionamides, functionalized amino acids, and related compounds are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10632047     DOI: 10.1016/s0968-0896(99)00186-8

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

Review 1.  Lacosamide.

Authors:  Pamela Doty; G David Rudd; Thomas Stoehr; Dirk Thomas
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

2.  Defining the structural parameters that confer anticonvulsant activity by the site-by-site modification of (R)-N'-benzyl 2-amino-3-methylbutanamide.

Authors:  Amber M King; Marc De Ryck; Rafal Kaminski; Anne Valade; James P Stables; Harold Kohn
Journal:  J Med Chem       Date:  2011-09-13       Impact factor: 7.446

3.  New treatment option for partial-onset seizures: efficacy and safety of lacosamide.

Authors:  Steve S Chung
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

4.  Clinical perspectives on lacosamide.

Authors:  Jonathan J Halford; Marc Lapointe
Journal:  Epilepsy Curr       Date:  2009 Jan-Feb       Impact factor: 7.500

5.  Differential regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by GSK3ß and CDK5 following traumatic brain injury.

Authors:  Sarah M Wilson; Seul Ki Yeon; Xiao-Fang Yang; Ki Duk Park; Rajesh Khanna
Journal:  Front Cell Neurosci       Date:  2014-05-28       Impact factor: 5.505

6.  Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety.

Authors:  Christoph Kellinghaus
Journal:  Ther Clin Risk Manag       Date:  2009-09-24       Impact factor: 2.423

7.  The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth.

Authors:  Sarah M Wilson; Aubin Moutal; Ohannes K Melemedjian; Yuying Wang; Weina Ju; Liberty François-Moutal; May Khanna; Rajesh Khanna
Journal:  Front Cell Neurosci       Date:  2014-07-24       Impact factor: 5.505

8.  Modulation of CRMP2 via (S)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease.

Authors:  Katherine A White; Jacob T Cain; Helen Magee; Seul Ki Yeon; Ki Duk Park; Rajesh Khanna; Jill M Weimer
Journal:  Health Psychol Behav Med       Date:  2019-04-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.